<DOC>
	<DOCNO>NCT01233921</DOCNO>
	<brief_summary>RATIONALE : Growth factor , palifermin , may prevent chronic graft-versus-host disease cause donor stem cell transplant . PURPOSE : This randomized clinical trial study palifermin prevent chronic graft-versus-host disease patient undergone donor stem cell transplant hematologic cancer</brief_summary>
	<brief_title>Palifermin Preventing Chronic Graft-Versus-Host Disease Patients Who Have Undergone Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . To evaluate pharmacodynamic effect palifermin thymic function patient risk chronic graft-vs-host disease ( GVHD ) . II . To evaluate tolerability palifermin patient risk chronic GVHD . OUTLINE : Patients assign 1 2 group base whether wish receive palifermin . GROUP 1 : Patients receive palifermin intravenously ( IV ) day 1-3 absence unacceptable toxicity . GROUP 2 : Patients receive palifermin . After completion study treatment , patient follow day 7 , 14 , 21 , 28 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Survival 60 day allogeneic hematopoietic cell transplantation ( HCT ) growthfactor mobilize blood cell Current dose prednisone = &lt; 0.5 mg/kg equivalent systemic glucocorticoid treatment Ability remain care Seattle Cancer Care Alliance ( SCCA ) least 28 day enrollment study Able willing give inform consent Presence generalize rash involve 50 % body surface Prior diagnosis chronic GVHD require systemic immunosuppressive treatment Any prior local irradiation field include thymus ( total body irradiation allow ) History thymectomy Use rabbit antithymocyte globulin pretransplant condition regimen Use graft deplete T cell Any evidence recurrent persistent malignancy HCT Participation another study chronic GVHD primary endpoint Any prior history carcinoma Any infection improve appropriate treatment History palifermin intolerance A positive pregnancy test ( woman childbearing potential ) Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>